Johnston Asset Management Has Cut Jazz Pharmaceuticals Plc (JAZZ) Stake By $774,520; Last Week ORBCOMM Inc. (ORBC) Analysts

May 22, 2018 - By Robert Thomas

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Among 5 analysts covering ORBCOMM (NASDAQ:ORBC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ORBCOMM had 21 analyst reports since March 14, 2016 according to SRatingsIntel. Canaccord Genuity maintained the shares of ORBC in report on Thursday, August 3 with “Buy” rating. The stock has “Buy” rating by Northland Capital on Friday, November 3. The firm earned “Buy” rating on Thursday, January 11 by Canaccord Genuity. The stock of ORBCOMM Inc. (NASDAQ:ORBC) has “Buy” rating given on Monday, September 11 by Canaccord Genuity. Northland Capital maintained the stock with “Buy” rating in Friday, September 29 report. The stock has “Buy” rating by Northland Capital on Monday, August 28. The stock of ORBCOMM Inc. (NASDAQ:ORBC) has “Buy” rating given on Monday, June 12 by Canaccord Genuity. The rating was maintained by Northland Capital with “Buy” on Tuesday, January 16. The firm has “Buy” rating given on Wednesday, July 12 by Canaccord Genuity. The firm has “Buy” rating by Canaccord Genuity given on Thursday, May 3. See ORBCOMM Inc. (NASDAQ:ORBC) latest ratings:

03/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $15.0000 Maintain
16/04/2018 Broker: Canaccord Genuity Rating: Buy New Target: $15.0000 Maintain
01/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $15.0 Maintain
02/02/2018 Broker: Roth Capital Rating: Buy New Target: $14.0 Initiate
16/01/2018 Broker: Northland Capital Rating: Buy New Target: $15.0 Maintain
11/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $16.0 Maintain
28/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $16.0 Maintain

Johnston Asset Management Corp decreased Jazz Pharmaceuticals Plc (JAZZ) stake by 13.26% reported in 2017Q4 SEC filing. Johnston Asset Management Corp sold 5,780 shares as Jazz Pharmaceuticals Plc (JAZZ)’s stock rose 10.34%. The Johnston Asset Management Corp holds 37,800 shares with $5.09M value, down from 43,580 last quarter. Jazz Pharmaceuticals Plc now has $9.96 billion valuation. The stock decreased 0.87% or $1.46 during the last trading session, reaching $166.05. About 414,689 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 0.32% since May 22, 2017 and is downtrending. It has underperformed by 11.87% the S&P500.

Another recent and important ORBCOMM Inc. (NASDAQ:ORBC) news was published by Seekingalpha.com which published an article titled: “ORBCOMM’s (ORBC) CEO Marc Eisenberg on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018.

ORBCOMM Inc. provides machine-to-machine and Internet of things solutions in the United States, South America, Japan, Europe, and internationally. The company has market cap of $758.35 million. It offers solutions, including network connectivity, device management, and Web reporting applications that enable businesses and government agencies to track, monitor, and control and communicate with fixed and mobile assets. It currently has negative earnings. The firm also provides satellite automatic identification service data services for vessel navigation and to enhance maritime safety using various network platforms, including its own constellation of low-Earth orbit satellites, and accompanying ground infrastructure to government and commercial customers.

Since January 5, 2018, it had 0 insider buys, and 15 insider sales for $1.06 million activity. Milcos Constantine sold $9,637 worth of ORBCOMM Inc. (NASDAQ:ORBC) on Wednesday, March 7. 5,000 ORBCOMM Inc. (NASDAQ:ORBC) shares with value of $47,040 were sold by Eisenberg Jerome B. COSTANTINI ROBERT G also sold $36,132 worth of ORBCOMM Inc. (NASDAQ:ORBC) on Wednesday, March 7. The insider Malone Craig sold $24,092. The insider Eisenberg Marc sold $261,023. Le Brun Christian sold $30,097 worth of stock. $100,648 worth of ORBCOMM Inc. (NASDAQ:ORBC) shares were sold by Stolte John J Jr.

The stock increased 1.47% or $0.14 during the last trading session, reaching $9.67. About 257,619 shares traded. ORBCOMM Inc. (NASDAQ:ORBC) has risen 5.65% since May 22, 2017 and is uptrending. It has underperformed by 5.90% the S&P500.

Investors sentiment increased to 1.38 in Q4 2017. Its up 0.07, from 1.31 in 2017Q3. It increased, as 12 investors sold ORBCOMM Inc. shares while 35 reduced holdings. 25 funds opened positions while 40 raised stakes. 53.88 million shares or 2.38% less from 55.19 million shares in 2017Q3 were reported. Thrivent Financial For Lutherans reported 471,800 shares. Alliancebernstein Lp holds 0% of its portfolio in ORBCOMM Inc. (NASDAQ:ORBC) for 75,400 shares. Moreover, Ubs Asset Mgmt Americas Inc has 0% invested in ORBCOMM Inc. (NASDAQ:ORBC) for 42,542 shares. State Street Corporation reported 0% stake. Teachers Retirement Of The State Of Kentucky reported 59,835 shares. Proshare Advisors Limited Liability Corporation reported 16,094 shares. Trexquant Investment Ltd Partnership invested in 44,477 shares or 0.05% of the stock. Mutual Of America Ltd Company, New York-based fund reported 906,793 shares. Mufg Americas Corporation holds 2,890 shares. Vestor Capital Ltd Liability Corporation has 0.01% invested in ORBCOMM Inc. (NASDAQ:ORBC). 205,000 are owned by Millrace Asset Grp Inc. Citigroup Inc invested 0% of its portfolio in ORBCOMM Inc. (NASDAQ:ORBC). Bancorporation Of Nova Scotia holds 0% of its portfolio in ORBCOMM Inc. (NASDAQ:ORBC) for 73,727 shares. Shufro Rose & Communication Limited Liability reported 0.04% in ORBCOMM Inc. (NASDAQ:ORBC). 348,530 are owned by Schwab Charles Invest Incorporated.

Analysts await Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to report earnings on August, 14. They expect $2.87 EPS, up 66.86% or $1.15 from last year’s $1.72 per share. JAZZ’s profit will be $172.18M for 14.46 P/E if the $2.87 EPS becomes a reality. After $2.63 actual EPS reported by Jazz Pharmaceuticals plc for the previous quarter, Wall Street now forecasts 9.13% EPS growth.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Nasdaq.com which released: “3 Biotechs on the FDA’s Naughty List That Should Be on Investors’ Buy Lists” on May 22, 2018, also Bizjournals.com with their article: “Peninsula drug maker swings $110 million deal for voucher” published on April 30, 2018, Bizjournals.com published: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” on May 17, 2018. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Fool.com and their article: “3 Top Biotech Stocks to Buy in May” published on May 09, 2018 as well as Seekingalpha.com‘s news article titled: “Jazz Pharmaceuticals Plc (JAZZ) Q1 2018 Results – Earnings Call Transcript” with publication date: May 09, 2018.

Investors sentiment increased to 1.09 in Q4 2017. Its up 0.06, from 1.03 in 2017Q3. It increased, as 30 investors sold JAZZ shares while 89 reduced holdings. 49 funds opened positions while 81 raised stakes. 52.98 million shares or 1.12% less from 53.58 million shares in 2017Q3 were reported. Toronto Dominion Bankshares invested in 3,541 shares. Panagora Asset Mngmt owns 1,341 shares or 0% of their US portfolio. Reilly Fincl Ltd holds 23 shares or 0% of its portfolio. 1,753 were accumulated by Dearborn Ptnrs Ltd Com. The Texas-based Maverick Cap Ltd has invested 0.07% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Gateway Advisers Ltd Limited Liability Company, Ohio-based fund reported 54,024 shares. Cubist Systematic Strategies Ltd Com reported 6,518 shares. Consolidated Investment Group Llc reported 0.18% stake. Howe And Rusling holds 611 shares or 0.01% of its portfolio. Macquarie Gru holds 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 1,800 shares. Adell Harriman Carpenter has 11,915 shares for 0.34% of their portfolio. 2,201 were reported by Pacad Inv Ltd. Sei Invs holds 0% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 5,513 shares. Thompson Inv Mngmt Inc accumulated 0.14% or 5,800 shares. Numeric Invsts Lc owns 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 2,200 shares.

Among 23 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 19 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Jazz Pharmaceuticals had 84 analyst reports since August 3, 2015 according to SRatingsIntel. RBC Capital Markets maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday, August 7 with “Buy” rating. The firm earned “Buy” rating on Wednesday, June 7 by BMO Capital Markets. The rating was maintained by UBS on Wednesday, November 8 with “Buy”. The firm has “Buy” rating by Cowen & Co given on Wednesday, June 7. The stock has “Buy” rating by Cantor Fitzgerald on Monday, May 7. Cantor Fitzgerald maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Tuesday, August 29 with “Buy” rating. The rating was maintained by BMO Capital Markets on Thursday, January 11 with “Buy”. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Wednesday, August 9 by Deutsche Bank. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Outperform” rating given on Wednesday, May 9 by BMO Capital Markets. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Buy” rating by Cowen & Co on Monday, October 23.

Since December 11, 2017, it had 0 buys, and 21 selling transactions for $4.95 million activity. 700 shares were sold by Young Matthew P., worth $109,207. MILLER MICHAEL PATRICK sold $27,998 worth of stock. WILSON KAREN J sold 3,899 shares worth $604,345. $150,010 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares were sold by COZADD BRUCE C. Treacy Paul had sold 877 shares worth $122,446. Another trade for 9,000 shares valued at $1.26M was made by ENRIGHT PATRICK G on Monday, December 11.

Johnston Asset Management Corp increased Broadcom Ltd stake by 10,957 shares to 958,870 valued at $246.33 million in 2017Q4. It also upped Albemarle Corp (NYSE:ALB) stake by 28,235 shares and now owns 314,072 shares. Schlumberger Ltd (NYSE:SLB) was raised too.

ORBCOMM Inc. (NASDAQ:ORBC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: